Israel - Ibrani - Ministry of Health

j-c health care ltd - bosentan - טבליות מצופות פילם - bosentan 125 mg - bosentan - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv.reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease

Israel - Ibrani - Ministry of Health

trima israel pharmaceutical products maabarot ltd - topiramate - טבליה - topiramate 25 mg - topiramate - topiramate - in adjunctive therapy of adults and children (from 2 years) with partial seizures and generalized tonic-clonic seizures. in adjunctive therapy of seizures with lennox-gastaut syndrome in adults and children. topitim is indicated as monotherapy in patients with newly diagnosed epilepsy in children aged 7 years and above or for conversion to monotherapy in patients with epilepsy. topitrim is indicated in adults for the prevention of migraines. the use of topitrim in the acute treatment of migraine has not been studied.

Israel - Ibrani - Ministry of Health

trima israel pharmaceutical products maabarot ltd - topiramate - טבליה - topiramate 50 mg - topiramate - topiramate - in adjunctive therapy of adults and children (from 2 years) with partial seizures and generalized tonic-clonic seizures. in adjunctive therapy of seizures with lennox-gastaut syndrome in adults and children. topitim is indicated as monotherapy in patients with newly diagnosed epilepsy in children aged 7 years and above or for conversion to monotherapy in patients with epilepsy. topitrim is indicated in adults for the prevention of migraines. the use of topitrim in the acute treatment of migraine has not been studied.

Israel - Ibrani - Ministry of Health

trima israel pharmaceutical products maabarot ltd - topiramate - טבליה - topiramate 100 mg - topiramate - topiramate - in adjunctive therapy of adults and children (from 2 years) with partial seizures and generalized tonic-clonic seizures. in adjunctive therapy of seizures with lennox-gastaut syndrome in adults and children. topitim is indicated as monotherapy in patients with newly diagnosed epilepsy in children aged 7 years and above or for conversion to monotherapy in patients with epilepsy. topitrim is indicated in adults for the prevention of migraines. the use of topitrim in the acute treatment of migraine has not been studied.

Israel - Ibrani - Ministry of Health

trima israel pharmaceutical products maabarot ltd - topiramate - טבליה - topiramate 200 mg - topiramate - topiramate - in adjunctive therapy of adults and children (from 2 years) with partial seizures and generalized tonic-clonic seizures. in adjunctive therapy of seizures with lennox-gastaut syndrome in adults and children. topitim is indicated as monotherapy in patients with newly diagnosed epilepsy in children aged 7 years and above or for conversion to monotherapy in patients with epilepsy. topitrim is indicated in adults for the prevention of migraines. the use of topitrim in the acute treatment of migraine has not been studied.

Israel - Ibrani - Ministry of Health

cts chemical industries ltd, israel - carbocisteine - לכסניה - carbocisteine 375 mg - carbocisteine - carbocisteine - treatment of disorders of the respiratory tract characterised by excessive or viscous mucus.

Israel - Ibrani - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

Israel - Ibrani - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 10 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

Israel - Ibrani - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 2.5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

Israel - Ibrani - Ministry of Health

eli lilly israel ltd, israel - ixekizumab - תמיסה להזרקה - ixekizumab 80 mg / 1 ml - ixekizumab